SciClone Pharmaceuticals Debuts in US$281 Million Hong Kong IPO
March 03, 2021
Hong Kong – Paul Hastings, a leading global law firm, announced today that it has advised Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited and Credit Suisse (Hong Kong) Limited as the joint sponsors on the US$281 million global offering and initial public offering of SciClone Pharmaceuticals (Holdings) Limited on the Main Board of the Hong Kong Stock Exchange.
SciClone Pharmaceuticals is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the largest and fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection.
Our sophisticated Securities and Capital Markets practice is one of the most active in Asia, with a substantial market share of Hong Kong IPOs. Paul Hastings has advised some of the most representative biotech and healthcare companies on their listings in Hong Kong, including SinoMab BioScience Limited, a biotech company listed under Chapter 18A, Ascletis Pharma, the first listing under Chapter 18A, Jinxin Fertility Group, the first assisted reproductive services company listed in Hong Kong, and CanSino Biologics, the first vaccine company listed on the Hong Kong Stock Exchange.
The Paul Hastings team was led by Raymond Li, global partner and chair of Greater China, corporate partners Vincent Wang and Chaobo Fan, with support from associates Crystal Liu, Jessica Lam and Jing Du.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.